Left Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients and Study Design
2.2. Statistical Analysis
3. Results
3.1. Population
3.2. Surgical Procedures
3.3. Surgical and Pathological Outcomes
3.4. Morbidities
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tozzi, R.; Traill, Z.; Campanile, R.G.; Ferrari, F.; Majd, H.S.; Nieuwstad, J.; Hardern, K.; Gubbala, K. Porta hepatis peritonectomy and hepato–celiac lymphadenectomy in patients with stage IIIC–IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes. Gynecol. Oncol. 2016, 143, 35–39. [Google Scholar] [CrossRef] [PubMed]
- Eisenhauer, E.L.; Abu-Rustum, N.R.; Sonoda, Y.; Levine, D.A.; Poynor, E.A.; Aghajanian, C.; Jarnagin, W.R.; DeMatteo, R.P.; D’Angelica, M.I.; Barakat, R.R. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol. Oncol. 2006, 103, 1083–1090. [Google Scholar] [CrossRef]
- Lim, M.C.; Kang, S.; Lee, K.S.; Han, S.S.; Park, S.J.; Seo, S.S.; Park, S.Y. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol. Oncol. 2009, 112, 28–34. [Google Scholar] [CrossRef] [PubMed]
- Chi, D.S.; Franklin, C.C.; Levine, D.A.; Akselrod, F.; Sabbatini, P.; Jarnagin, W.R.; DeMatteo, R.; Poynor, E.A.; Abu-Rustum, N.R.; Barakat, R.R. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: A change in surgical approach. Gynecol. Oncol. 2004, 94, 650–654. [Google Scholar] [CrossRef]
- Song, Y.J.; Lim, M.C.; Kang, S.; Seo, S.-S.; Park, J.W.; Choi, H.S.; Park, S.-Y. Total colectomy as part of primary cytoreductive surgery in advanced Müllerian cancer. Gynecol. Oncol. 2009, 114, 183–187. [Google Scholar] [CrossRef] [PubMed]
- Bacalbasa, N.; Dima, S.; Brasoveanu, V.; David, L.; Balescu, I.; Purnichescu-Purtan, R.; Popescu, I. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J. Surg. Oncol. 2015, 13, 235. [Google Scholar] [CrossRef] [PubMed]
- Kostov, S.; Selçuk, I.; Watrowski, R.; Dineva, S.; Kornovski, Y.; Slavchev, S.; Ivanova, Y.; Yordanov, A. Neglected Anatomical Areas in Ovarian Cancer: Significance for Optimal Debulking Surgery. Cancers 2024, 16, 285. [Google Scholar] [CrossRef]
- O’Neill, A.C.; Somarouthu, B.; Tirumani, S.H.; Braschi-Amirfarzan, M.; Van den Abbeele, A.D.; Ramaiya, N.H.; Shinagare, A.B. Patterns and prognostic importance of hepatic involvement in patients with serous ovarian cancer: A single-institution experience with 244 patients. Radiology 2017, 282, 160–170. [Google Scholar] [CrossRef]
- Eisenkop, S.M.; Spirtos, N.M.; Lin, W.-C.M. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol. Oncol. 2006, 100, 344–348. [Google Scholar] [CrossRef]
- Couinaud, C. Liver anatomy: Portal (and suprahepatic) or biliary segmentation. Dig. Surg. 1999, 16, 459–467. [Google Scholar] [CrossRef]
- Gasparri, M.L.; Grandi, G.; Bolla, D.; Gloor, B.; Imboden, S.; Panici, P.B.; Mueller, M.D.; Papadia, A. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. J. Cancer Res. Clin. Oncol. 2016, 142, 1509–1520. [Google Scholar] [CrossRef] [PubMed]
- Luna-Abanto, J.; García Ruiz, L.; Laura Martinez, J.; Álvarez Larraondo, M.; Villoslada Terrones, V. Liver resection as part of cytoreductive surgery for ovarian cancer. J. Gynecol. Surg. 2020, 36, 70–75. [Google Scholar] [CrossRef] [PubMed]
- Merideth, M.A.; Cliby, W.A.; Keeney, G.L.; Lesnick, T.G.; Nagorney, D.M.; Podratz, K.C. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol. Oncol. 2003, 89, 16–21. [Google Scholar] [CrossRef]
- Garbar, V.; Newton, B.W. Anatomy, Abdomen and Pelvis, Falciform Ligament; StatPearls Publishing: Treasure Island, FL, USA, 2019. [Google Scholar]
- Dindo, D. The Clavien–Dindo classification of surgical complications. In Treatment of Postoperative Complications after Digestive Surgery; Springer: London, UK, 2014; pp. 13–17. [Google Scholar]
- Li, B.; Qin, Y.; Qiu, Z.; Ji, J.; Jiang, X. A cohort study of hepatectomy-related complications and prediction model for postoperative liver failure after major liver resection in 1,441 patients without obstructive jaundice. Ann. Transl. Med. 2021, 9, 305. [Google Scholar] [CrossRef] [PubMed]
- Chi, D.S.; Zivanovic, O.; Levinson, K.L.; Kolev, V.; Huh, J.; Dottino, J.; Gardner, G.J.; Leitao, M.M., Jr.; Levine, D.A.; Sonoda, Y. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol. Oncol. 2010, 119, 38–42. [Google Scholar] [CrossRef]
- Suh, D.H.; Kim, N.K.; Kim, K.D.; No, J.H.; Kim, Y.B. EP243/# 1167 Relative extensiveness of peritoneal seeding versus lymph node metastasis as a prognostic factor in advanced-stage ovarian cancer. Int. J. Gynecol. Cancer 2022, 32, A148. [Google Scholar]
- Turco, G.; Chiesa, G.; de Manzoni, G. Echographic anatomy of the greater peritoneal cavity and its recesses. La Radiol. Med. 1988, 75, 46–55. [Google Scholar]
- Chandrashekhara, S.H.; Triveni, G.S.; Kumar, R. Imaging of peritoneal deposits in ovarian cancer: A pictorial review. World J. Radiol. 2016, 8, 513. [Google Scholar] [CrossRef] [PubMed]
- Salani, R.; Axtell, A.; Gerardi, M.; Holschneider, C.; Bristow, R.E. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 2008, 108, 271–275. [Google Scholar] [CrossRef]
- Zorzetto, G.; Coppola, A.; Molinelli, V.; Angeretti, M.G.; Casarin, J.; Fontana, F.; Piacentino, F.; Carcano, G.; Ghezzi, F.; Venturini, M. Spectral CT in peritoneal carcinomatosis from ovarian cancer: A tool for differential diagnosis of small nodules? Eur. Radiol. Exp. 2022, 6, 45. [Google Scholar] [CrossRef] [PubMed]
- Avesani, G.; Arshad, M.; Lu, H.; Fotopoulou, C.; Cannone, F.; Melotti, R.; Aboagye, E.; Rockall, A. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival. La Radiol. Med. 2020, 125, 770–776. [Google Scholar] [CrossRef] [PubMed]
- Iyer, V.R.; Lee, S.I. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. Am. J. Roentgenol. 2010, 194, 311–321. [Google Scholar] [CrossRef] [PubMed]
- Selçuk, İ.; Başarır, Z.Ö.; Ohri, N.; Akar, B.; Çalışkan, E.; Güngör, T. Comparative surgical resection of the ligamentum teres hepatis in a cadaveric model and a patient with ovarian cancer. J. Turk. Ger. Gynecol. Assoc. 2019, 20, 62. [Google Scholar] [CrossRef]
- Cavaness, K.M.; Chapman, W.C. Management of Metastatic Colorectal Cancer to the Liver. In Shackelford’s Surgery of the Alimentary Tract, 2 Volume Set; Elsevier: Amsterdam, The Netherlands, 2019; pp. 2074–2092. [Google Scholar]
- Rosati, A.; De Rose, A.M.; Gallotta, V.; Giannarelli, D.; Ghirardi, V.; Pavone, M.; De Palma, A.; Conte, C.; Marchetti, C.; Gallucci, V.; et al. Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer. Gynecol. Oncol. 2024, 187, 98–104. [Google Scholar] [CrossRef] [PubMed]
- Ibukuro, K.; Fukuda, H.; Tobe, K.; Akita, K.; Takeguchi, T. The vascular anatomy of the ligaments of the liver: Gross anatomy, imaging and clinical applications. Br. J. Radiol. 2016, 89, 20150925. [Google Scholar] [CrossRef]
- Lin, H.; Chen, W.-H.; Wu, C.-H.; Ou, Y.-C.; Chen, Y.-J.; Chen, Y.-Y.; Lin, Y.-H.; Fu, H.-C. Impact of the time interval between primary debulking surgery and start of adjuvant chemotherapy in advanced epithelial ovarian cancer. Cancer Manag. Res. 2021, 13, 5413–5422. [Google Scholar] [CrossRef]
- Liu, X.; Zhao, Y.; Jiao, X.; Yu, Y.; Li, R.; Zeng, S.; Chi, J.; Ma, G.; Huo, Y.; Li, M. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A multicenter real-world study. J. Ovar. Res. 2023, 16, 121. [Google Scholar] [CrossRef]
- Schwarz, J.K.; Grigsby, P.W.; Dehdashti, F.; Delbeke, D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J. Nucl. Med. 2009, 50 (Suppl. S1), 64S–73S. [Google Scholar] [CrossRef]
- Kitajima, K.; Murakami, K.; Yamasaki, E.; Kaji, Y.; Fukasawa, I.; Inaba, N.; Sugimura, K. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: Comparison with enhanced CT. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1912–1920. [Google Scholar] [CrossRef]
- Javitt, M.C. ACR Appropriateness Criteria® on Staging and Follow-Up of Ovarian Cancer. J. Am. Coll. Radiol. 2007, 4, 586–589. [Google Scholar] [CrossRef]
- Yoshida, Y.; Kurokawa, T.; Kawahara, K.; Tsuchida, T.; Okazawa, H.; Fujibayashi, Y.; Yonekura, Y.; Kotsuji, F. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am. J. Roentgenol. 2004, 182, 227–233. [Google Scholar] [CrossRef] [PubMed]
- Sebastian, S.; Lee, S.I.; Horowitz, N.S.; Scott, J.A.; Fischman, A.J.; Simeone, J.F.; Fuller, A.F.; Hahn, P.F. PET–CT vs. CT alone in ovarian cancer recurrence. Abdom. Imaging 2008, 33, 112–118. [Google Scholar] [CrossRef] [PubMed]
- Ea, H. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur. J. Radiol. 2005, 56, 263–268. [Google Scholar]
- Gu, P.; Pan, L.-L.; Wu, S.-Q.; Sun, L.; Huang, G. CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis. Eur. J. Radiol. 2009, 71, 164–174. [Google Scholar] [CrossRef] [PubMed]
Variables | No. [Range] (%) |
---|---|
Age at diagnosis (year) | 58 [44–69] |
Histologic type | |
Serous adenocarcinoma | 14 (82.4%) |
Endometrioid | 1 (5.9%) |
Clear cell | 1 (5.9%) |
Carcinosarcoma | 1 (5.9%) |
Tumor grade | |
2 | 7 (41.2%) |
3 | 10 (58.8%) |
FIGO stage | |
IIIB | 1 (5.9%) |
IIIC | 1 (5.9%) |
IVB | 15 (88.2%) |
Preoperative serum CA-125 (IU/ml) | 1234 [38–20,351] |
The timing of CRS 1 | |
Upfront CRS | 12 (70.6%) |
Interval CRS | 5 (29.4%) |
Comorbidities | |
Hypertension | 4 (23.5%) |
Diabetes Mellitus | 3 (17.6%) |
Cardiovascular disease | 1 (5.9%) |
Tuberculosis | 2 (11.8%) |
Liver parenchymal invasion by preoperative imaging | |
Yes | 3 (17.6%) |
No | 14 (82.4%) |
Type of Procedures | No. (%) |
---|---|
Hysterectomy | 15 (88%) |
Salpingo-oophorectomy | 17 (100%) |
Pelvic lymphadenectomy | 13 (76%) |
Para-aortic lymphadenectomy | 17 (100%) |
Supracolic omentectomy | 13 (76%) |
Splenectomy | 12 (71%) |
Distal pancreatectomy | 4 (24%) |
Cholecystectomy | 12 (71%) |
Diaphragmatic peritonectomy | 10 (59%) |
Low anterior resection | 7 (41%) |
Appendectomy | 8 (47%) |
Surgical Outcome | No. [Range] (%) |
---|---|
Operative time (min) | 507 [311–760] |
Estimated blood loss (mL) | 900 [500–3600] |
Postoperative ICU 1 stay (day) | 1 [0–2] |
Hospitalization after operation (day) | 14 [8–27] |
Time to subsequent chemotherapy (day) | 21 [12–35] |
Residual disease | |
Microscopic | 14 (82.4%) |
Macroscopic < 1 cm | 3 (17.6%) |
Pathologically Proven Tumor Involvement | No. (%) |
No tumor remained | 1 (5.9%) |
Liver parenchyma | 10 (58.8%) |
Glisson’s Capsule or hilum | 14 (82.4%) |
Falciform ligament | 11 (64.7%) |
Gall bladder | 5 (29.4%) |
Variables | No. (%) | Management |
---|---|---|
Severe complication 1 | ||
Gastrointestinal tract bleeding (stress ulcer) | 1 (6%) | Embolization |
Mild complication 2 | ||
Infection | 2 (12%) | Antibiotics |
Ileus | 5 (29%) | Nasogastric tube insertion |
Thromboembolism | 4 (24%) | Anticoagulants |
Subhepatic hemorrhage/hematoma | 1 (6%) | Transfusion and observation |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, U.; Bae, J.K.; Kim, J.; Kim, J.H.; Kim, S.H.; Han, S.-S.; Park, H.M.; Park, S.-Y.; Lim, M.C. Left Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer. Cancers 2024, 16, 3036. https://doi.org/10.3390/cancers16173036
Kim U, Bae JK, Kim J, Kim JH, Kim SH, Han S-S, Park HM, Park S-Y, Lim MC. Left Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer. Cancers. 2024; 16(17):3036. https://doi.org/10.3390/cancers16173036
Chicago/Turabian StyleKim, Uisuk, Jae Kyung Bae, Junhwan Kim, Ji Hyun Kim, Seong Hoon Kim, Sung-Sik Han, Hyeong Min Park, Sang-Yoon Park, and Myong Cheol Lim. 2024. "Left Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer" Cancers 16, no. 17: 3036. https://doi.org/10.3390/cancers16173036